Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study

BACKGROUND: This study aims to evaluate the association between thromboembolic events and hemorrhagic stroke following BNT162b2 and CoronaVac vaccination. METHODS: Patients with incident thromboembolic events or hemorrhagic stroke within 28 days of covid-19 vaccination or SARS-CoV-2 positive test du...

Descripción completa

Detalles Bibliográficos
Autores principales: Chui, Celine Sze Ling, Fan, Min, Wan, Eric Yuk Fai, Leung, Miriam Tim Yin, Cheung, Edmund, Yan, Vincent Ka Chun, Gao, Le, Ghebremichael-Weldeselassie, Yonas, Man, Kenneth K.C., Lau, Kui Kai, Lam, Ivan Chun Hang, Lai, Francisco Tsz Tsun, Li, Xue, Wong, Carlos King Ho, Chan, Esther W., Cheung, Ching-Lung, Sing, Chor-Wing, Lee, Cheuk Kwong, Hung, Ivan Fan Ngai, Lau, Chak Sing, Chan, Joseph Yat Sun, Lee, Michael Kang-Yin, Mok, Vincent Chung Tong, Siu, Chung-Wah, Chan, Lot Sze Tao, Cheung, Terence, Chan, Frank Ling Fung, Leung, Anskar Yu-Hung, Cowling, Benjamin John, Leung, Gabriel Matthew, Wong, Ian Chi Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233170/
https://www.ncbi.nlm.nih.gov/pubmed/35770253
http://dx.doi.org/10.1016/j.eclinm.2022.101504
Descripción
Sumario:BACKGROUND: This study aims to evaluate the association between thromboembolic events and hemorrhagic stroke following BNT162b2 and CoronaVac vaccination. METHODS: Patients with incident thromboembolic events or hemorrhagic stroke within 28 days of covid-19 vaccination or SARS-CoV-2 positive test during 23 February to 30 September 2021 were included. The incidence per 100,000 covid-19 vaccine doses administered and SARS-CoV-2 test positive cases were estimated. A modified self-controlled case series (SCCS) analysis using the data from the Hong Kong territory-wide electronic health and vaccination records. Seasonal effect was adjusted by month. FINDINGS: A total of 5,526,547 doses of BNT162b2 and 3,146,741 doses of CoronaVac were administered. A total of 334 and 402 thromboembolic events, and 57 and 49 hemorrhagic stroke cases occurred within 28 days after BNT162b2 and CoronaVac vaccination, respectively. The crude incidence of thromboembolic events and hemorrhagic stroke per 100,000 doses administered for both covid-19 vaccines were smaller than that per 100,000 SARS-CoV-2 test positive cases. The modified SCCS detected an increased risk of hemorrhagic stroke in BNT162b2 14-27 days after first dose with adjusted IRR of 2.53 (95% CI 1.48-4.34), and 0-13 days after second dose with adjusted IRR 2.69 (95% CI 1.54-4.69). No statistically significant risk was observed for thromboembolic events for both vaccines. INTERPRETATION: We detected a possible safety signal for hemorrhagic stroke following BNT162b2 vaccination. The incidence of thromboembolic event or hemorrhagic stroke following vaccination is lower than that among SARS-CoV-2 test positive cases; therefore, vaccination against covid-19 remains an important public health intervention. FUNDING: This study was funded by a research grant from the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (reference COVID19F01).

Ejemplares similares